Alimera Sciences buys US rights to EyePoint’s Yutiq
Pharmaceutical Technology
MAY 19, 2023
It received approval from the US Food and Drug Administration in October 2018. EyePoint Pharmaceuticals will also receive potential royalties on the combined net sales of Iluvien and Yutiq in the US from 2025 to 2028. will be paid in equal quarterly instalments in 2024.
Let's personalize your content